Glucocorticoid-induced osteoporosis

被引：18

作者：

Silverman S.L. ^{[1
]}

Lane N.E. ^{[1
]}

机构：

[1] Cedars-Sinai/UCLA, OMC Clinical Research Center, Beverly Hills, CA 90211

来源：

Current Osteoporosis Reports | 2009年 / 7卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Bone Mineral Density; Glucocorticoid; Vertebral Fracture; Alendronate; Zoledronic Acid;

D O I：

10.1007/s11914-009-0005-4

中图分类号：

学科分类号：

摘要：

Glucocorticoid treatment can alter bone metabolism, reduce bone strength, and increase the risk for osteoporotic fractures. Risk factors for glucocorticoid-induced osteoporosis (GIO) include older age, high doses, and longer duration of glucocorticoid use. The bone loss that accompanies glucocorticoid use is rapid, and early treatment with bone-sparing agents can prevent bone loss and reduce fracture risk. Several randomized controlled clinical trials have found prevention and treatment of GIO with bisphosphonates, and recently the treatment of GIO with teriparatide, to be effective. This article reviews current information on the epidemiology, pathophysiology, and clinical studies that support using bone-active agents to prevent and treat GIO. © Current Medicine Group, LLC 2009.

引用

页码：23 / 26

页数：3

共 34 条

[1]

Van Staa T.P., Leufkens H.G., Abenhaim L., Et al., Use of oral corticosteroids in the United Kingdom, QJM, 93, pp. 105-111, (2000)

[2]

Van Staa T.P., Leufkens H.G., Cooper C., The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis, Osteoporos Int, 13, pp. 777-787, (2002)

[3]

Van Staa T.P., Leufkens H.G., Abenhaim L., Et al., Use of oral corticosteroids and risk of fractures, J Bone Miner Res, 15, pp. 993-1000, (2000)

[4]

Van Staa T.P., Leufkens H.G., Abenhaim L., Et al., Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses, Rheumatology (Oxford), 39, pp. 1383-1389, (2000)

[5]

Van Staa T.P., Laan R.F., Barton I.P., Et al., Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy, Arthritis Rheum, 48, pp. 3224-3229, (2003)

[6]

Kanis J.A., Johansson H., Oden A., Et al., A meta-analysis of prior corticosteroid use and fracture risk, J Bone Miner Res, 19, pp. 893-899, (2004)

[7]

Van Staa T.P., Leufkens H.G., Cooper C., Use of inhaled corticosteroids and risk of fractures, J Bone Miner Res, 16, pp. 581-588, (2001)

[8]

Wong C.A., Walsh L.J., Smith C.J., Et al., Inhaled corticosteroid use and bone mineral density in asthma, Lancet, 355, pp. 1399-1403, (2000)

[9]

Herrala J., Puolijoki H., Impivaara O., Et al., Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate, Bone, 15, pp. 621-623, (1994)

[10]

Ip M., Lam K., Yam L., Et al., Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids, Chest, 105, pp. 1722-1727, (1994)

← 1 2 3 4 →